Hormonal Prerequisites: Why Short-Term Methods Need an Endocrine Frame

Status: draft compiled 2026-04-20. Confidence tiers follow the project-wide convention: C1 = Phase 3 / multiple meta-analyses; C2 = multiple RCTs; C3 = small RCT or strong open-label; C4 = case series or anecdote; C5 = disproven.

Short-term hair removal only makes sense against the hormonal substrate that drives hair growth in the first place. A method that would look adequate on a body with sparse terminal hair looks hopeless on a body where androgens keep pushing new vellus follicles into terminal differentiation every month. This chapter sets up the endocrine context so that the downstream method chapters (shaving, depilatories, waxing, threading, epilation) can be read as interventions on a moving substrate rather than as settled consumer choices.

The androgen axis and follicular fate

Terminal hair in androgen-sensitive regions (beard, chest, back, lower abdomen, inner thigh, pubic extension onto upper thigh, some forearm and posterior thigh) is primarily governed by dihydrotestosterone (DHT), not testosterone itself. DHT is produced locally in the follicle by 5α-reductase type 1 (dominant in sebaceous and body follicles) and type 2 (dominant in genital skin, beard, and some prostate tissue). It binds the androgen receptor with roughly 3-5× the affinity of testosterone and has a much lower dissociation rate, so even modest intrafollicular DHT produces strong terminalisation signals. The clinical consequence is that serum testosterone can be a poor predictor of which follicles will terminalise — local 5α-reductase activity and androgen receptor density matter at least as much. Sources: Randall 2007, Semin Reprod Med, PMID 17487690; Sawaya & Price 1997. Confidence: C1.

Vellus follicles — the short, fine, lightly pigmented hair on most of the body — can convert to terminal follicles under androgen exposure. This is the biology behind adolescent beard and body-hair development, the slow densification of facial hair through the twenties, the hirsutism phenotype in hyperandrogenism, and the partial masculinisation of skin on gender-affirming testosterone. The reverse conversion, terminal back to vellus, is much slower and less reliable. Transfeminine patients on estrogenic HRT and antiandrogens usually experience softening and slowing of facial and body hair, but established beard follicles rarely miniaturise back to vellus on a useful cosmetic timescale, which is the underlying reason electrolysis and laser remain necessary in gender-affirming care even on optimal endocrine regimens. Sources: Wierckx et al 2014, J Sex Med, PMID 24438021; Giltay & Gooren 2000, J Clin Endocrinol Metab; WPATH SOC 8. Confidence: C2.

Why this matters for short-term methods

The practical consequence is that the observable "regrowth speed" a patient attributes to their razor or wax is really three processes layered on top of each other. The first is the follicle re-entering anagen and extruding a new shaft, which takes 2-8 weeks depending on body region and which is what people notice after waxing. The second is continued vellus-to-terminal conversion under ongoing androgen exposure, which adds new terminal shafts to the field over months and years and is what people feel when they say "more hair keeps appearing." The third is the recovery of shafts that were only partly damaged by a previous method, which happens on shorter timescales. These three clocks are independent and the endocrine environment mostly controls the second one. A transfeminine patient on spironolactone 100 mg/day plus estradiol for eighteen months will usually see a slowing of the second clock that makes every short-term method feel more effective, not because the razor is better but because fewer new terminal shafts are being recruited to cut. A woman with untreated PCOS will experience the opposite: every method feels as though it "does nothing" because the second clock is running continuously. Confidence: C2.

The further practical consequence is that medical management of the androgen axis is a legitimate adjunct to short-term hair removal even when permanent methods are planned later. It is not a replacement, because established terminal hair remains, but it changes what the short-term methods are asked to do. The Endocrine Society's 2018 hirsutism guideline and WPATH SOC 8 both frame antiandrogens as standard first-line care in their respective indications, and both note that the cosmetic effect plateaus around 6-12 months and leaves laser or electrolysis necessary for definitive clearance. Sources: Martin et al 2018, JCEM; WPATH SOC 8; Hembree et al 2017 Endocrine Society trans guideline. Confidence: C1.

Spironolactone

Spironolactone is an aldosterone antagonist whose clinical usefulness for hair comes from off-target androgen-receptor antagonism and weak 17α-hydroxylase / 17,20-lyase inhibition. Typical dosing for hirsutism is 50-200 mg/day, most often 100 mg/day; for transfeminine HRT in US practice, 100-200 mg/day is common alongside estradiol. Ferriman-Gallwey score reductions of 15-40% are reported at 6-12 months, with effect broadly comparable to finasteride 5 mg/day and superior to flutamide 250 mg/day in head-to-head RCTs. The 2016 Cochrane review and Swiglo's 2008 meta-analysis both support this. Sources: Cochrane Brown J et al 2016, CD000194.pub2; Swiglo 2008 meta-analysis; Martin et al 2018 Endocrine Society. Confidence: C1.

The safety signal that matters most for short-term hair-removal users is that routine potassium monitoring in healthy young women on spironolactone for androgen-mediated skin conditions has a low yield. Plovanich et al 2015, JAMA Dermatology looked at 974 women younger than 46 on spironolactone 50-200 mg/day for acne/hirsutism and found the hyperkalaemia rate indistinguishable from baseline. Risk does rise with renal impairment, concurrent ACE inhibitor or ARB use, potassium supplementation, and age over 45, which is why protocolised monitoring is still appropriate in those groups. Pregnancy is a contraindication because spironolactone crosses the placenta and antagonises androgen action in a male fetus; reliable contraception is part of the prescription, not an afterthought. Confidence: C1.

For transfeminine users, spironolactone's effect on short-term hair methods is indirect: it lowers the rate of new terminal-hair recruitment without destroying existing follicles, so it compounds with laser and electrolysis rather than competing with them. The common patient experience of "the same wax that used to wear off in three weeks now lasts six" after several months of HRT is consistent with this mechanism. Confidence: C3.

Cyproterone acetate

Cyproterone acetate (CPA) is not available in the US but is widely used in Canada, Europe, Australia, and much of Asia for hirsutism (25-100 mg/day), acne/androgenetic alopecia combinations, and transfeminine HRT (historically 50-100 mg/day, now commonly 10-25 mg/day or lower after the meningioma signal). Mechanistically it is a steroidal antiandrogen combining AR antagonism, progestogenic activity, and weak gonadotropin suppression, which makes it more potent than spironolactone per milligram and more likely to produce deep suppression of facial hair growth rate. Sources: EMA product information; Endocrine Society 2018; Wierckx et al 2014, PMID 24438021. Confidence: C1.

The safety signal that has reshaped CPA dosing globally is the dose-dependent meningioma risk. Weill et al 2021, BMJ 372:n37 examined a French national cohort of about 253,000 women exposed to CPA and found a cumulative-dose-dependent relationship: relative risk around 7× at ≥3 g cumulative exposure and around 20× at ≥60 g. Regulatory authorities in Europe and Canada responded by restricting high-dose indications and requiring MRI surveillance for long-term users. The low-dose end of the curve is less well characterised — the cohort was predominantly higher-dose — so long-term transfeminine users on 10 mg/day or less should consider the risk as present but uncertain, with MRI screening discussed individually. The other CPA safety signals worth noting are elevated VTE risk compared with levonorgestrel-containing COCs, rare fulminant hepatitis at higher doses, and depressed mood. Sources: Weill 2021 BMJ; EMA / ANSM 2020 safety review; EMA 2013 Diane-35 review. Confidence: C1.

5α-reductase inhibitors

Finasteride 2.5-5 mg/day (more commonly 2.5 mg for hirsutism) blocks 5α-reductase type 2 and modestly reduces Ferriman-Gallwey scores compared with placebo. Dutasteride 0.5 mg/day is a dual type 1 and type 2 inhibitor and produces slightly larger reductions in small head-to-head trials; Lumachi & Rondinone 2003, J Endocrinol Invest, PMID 12952360 reported about 6-point F-G reduction at six months for dutasteride versus about 4 for finasteride. Neither drug is first-line for hirsutism, both are pregnancy category X, and both depend on reliable contraception in any reproductive-age user. They have a modest additive role in reducing how hard the short-term methods have to work on the same body. Sources: Cochrane Brown 2016; Endocrine Society 2018. Confidence: C2.

In transfeminine practice, finasteride and dutasteride are sometimes added to estradiol + spironolactone or estradiol + cyproterone regimens to produce deeper local androgen suppression in skin. The effect on facial and body hair growth is modest and highly individual; expect slower regrowth rather than disappearance. Confidence: C3.

Combined oral contraceptives

COCs reduce free testosterone through ovarian androgen suppression (LH down, so ovarian androgen synthesis down) and hepatic SHBG elevation (so more testosterone is bound and inactive). Antiandrogenic progestins — drospirenone, cyproterone, dienogest — outperform older progestins (levonorgestrel, norgestrel) on hirsutism endpoints. The Endocrine Society 2018 guideline supports COC + spironolactone as first-line combination therapy for moderate to severe hirsutism; COC alone produces a modest 15-25% F-G reduction over 6-12 months, COC + antiandrogen is additive. Diane-35 (CPA 2 mg + ethinylestradiol 35 μg) remains the European workhorse despite elevated VTE risk; its first-line status has been restricted in several jurisdictions. Sources: Endocrine Society 2018; Cochrane Brown 2016; EMA 2013 Diane-35. Confidence: C1.

GnRH agonists and add-back

Leuprolide, triptorelin, and goserelin suppress pituitary LH and FSH and therefore ovarian androgen production. They are effective for severe hirsutism, especially when an ovarian source dominates, but they induce a reversible hypogonadal state with hot flashes, vaginal dryness, and bone-density loss. They are therefore usually reserved for refractory cases and combined with estrogen-progestogen "add-back" for bone and vasomotor protection. Cost, injection burden, and the need for add-back limit routine use. Sources: Heiner 1995, PMID 7539811; Endocrine Society 2018. Confidence: C2.

Eflornithine 13.9% cream

Eflornithine (α-difluoromethylornithine, DFMO; trade name Vaniqa in the US and several EU markets) is the only FDA-approved topical that slows unwanted facial hair growth. It is an irreversible inhibitor of ornithine decarboxylase (ODC), the rate-limiting enzyme converting ornithine to putrescine and the downstream spermidine and spermine polyamines. Polyamines are required for keratinocyte proliferation in the hair matrix; blocking them slows the shaft growth rate without destroying the follicle. Pivotal Phase 3 data (Shapiro & Lui 2001; Balfour & McClellan 2001) gave about 32-38% "marked improvement" on Physician's Global Assessment at 24 weeks versus about 8-9% with vehicle, with effect detectable by week 8. Stopping eflornithine returns growth to baseline within about 8 weeks. Sources: Shapiro & Lui 2001, PMID 11511817; Balfour & McClellan 2001, PMID 11705094; Vaniqa FDA label 2000. Confidence: C1.

Eflornithine is additive to laser rather than competitive with it. Hamzavi et al 2007, JAAD, PMID 17482708 ran a split-face RCT of 54 women with facial hair and found laser + eflornithine achieved faster clearance and higher success rates at 34 weeks (93.5% vs 67.9%). For short-term hair removal specifically, eflornithine reduces the visible regrowth rate between shave, wax, or thread sessions, which is perceived by users as "sessions lasting longer" rather than as any change in the follicle itself. It is wrong-direction for transmasculine beard growth; applying it to a growing beard would slow it down. Confidence: C1.

What the endocrine layer does and does not do

The short version is that hormonal modulation reduces how often the short-term methods are needed and how much new substrate they have to fight against, but it does not remove established terminal follicles. Laser or electrolysis is still required for definitive clearance. A reasonable reading is to treat hormonal management as the backdrop that makes short-term methods feel effective rather than futile, and to treat permanent methods as the only way to subtract terminal follicles from the field. Sources: WPATH SOC 8; Endocrine Society hirsutism 2018; Hembree 2017 Endocrine Society trans. Confidence: C2.